We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AMRX raised 2026 EBITDA and EPS guidance after Q1 earnings and revenue topped expectations.
Affordable Medicines targets 7%-8% growth in 2026, supported by 20-30 annual product launches.
Specialty revenue rose 23% in Q1, driven by Crexont growth and contributions from Brekiya.
Amneal Pharmaceuticals (AMRX - Free Report) opened 2026 with results that reinforced its steady execution story. The company is leaning on a diversified model that blends retail generics, higher-margin specialty brands, and a government-focused distribution business. That mix helps smooth out volatility that often hits single-product drug makers.
The setup for the rest of 2026 now hinges on two factors: whether profitability continues to climb on mix and discipline, and whether the company can keep its complex product cadence on track despite a tougher pricing backdrop in generics.
AMRX’s Q1 Beat Sets the Tone for 2026
In the first quarter of 2026, adjusted earnings were 27 cents per share, up 29% year over year. Results topped the Zacks Consensus Estimate of 17 cents. Total revenue was $723 million, up 4% year over year, and also came in ahead of the $713 million consensus mark.
The beat matters because it reflects momentum across multiple parts of the business, not a one-off benefit. Affordable Medicines grew modestly, Specialty posted a sharp increase, and AvKARE stayed sizeable even with a year-over-year decline. Together, that combination supports the view that operating progress is carrying into the full year.
Amneal’s Three-Segment Model Spreads Risk
Amneal runs three reportable segments: Affordable Medicines, Specialty, and AvKARE. Affordable Medicines develops, manufactures, and sells retail generics, injectables, and biosimilars across multiple dosage forms. Specialty markets branded therapies focused primarily on neurology and endocrine disorders. AvKARE distributes pharmaceuticals and other products to the U.S. federal government, retail, and institutional markets.
The diversification is visible in the revenue mix. In fiscal 2025, total net revenue was $3.0 billion, with Affordable Medicines at $1.7 billion, Specialty at $528.5 million, and AvKARE at $744.7 million. That balance reduces reliance on any single product line and supports steadier revenue and profit progress when one segment faces temporary headwinds.
AMRX Guidance Highlights Profitability Progress
For 2026, management expects net revenue of $3.05 billion to $3.15 billion. The updated outlook kept the revenue range unchanged, but raised profitability expectations. Adjusted EBITDA is now projected at $740 million to $770 million, up from $720 million to $760 million.
Adjusted earnings per share are now expected to be 95 cents to $1.05, up from 93 cents to $1.03. The higher EBITDA and earnings ranges point to improving mix and execution rather than simply counting on faster top-line growth. In practical terms, the company is signaling that higher-value products and operating discipline can carry more of the performance load in 2026.
Amneal’s Generics Pipeline Can Reaccelerate Growth
Affordable Medicines is expected to accelerate in 2026 and 2027 versus 2025 levels. Management expects the segment’s net revenue to grow 7% to 8% in 2026. A key driver is cadence: Amneal expects to launch 20 to 30 new products in Affordable Medicines each year, with an emphasis on complex products.
The pipeline also includes biosimilars. A notable 2026 opportunity is a biosimilar version of Novartis’ (NVS - Free Report) Xolair, which is under review. If approved, Amneal would have six biosimilars in the United States. That matters for investors because biosimilars and complex generics can offer a different growth and margin profile than “plain vanilla” launches, while still serving the broader demand for affordable medicines.
AMRX Injectables Expansion Adds Differentiation
Recent product actions highlight how dosage-form differentiation can set Amneal apart. On June 4, 2026, the FDA approved romidepsin injection solution supplied in single-dose, ready-to-use vials. The product is eligible for Competitive Generic Therapy designation, which provides 180 days of market exclusivity.
Management emphasized convenience benefits versus an existing powder form that requires mixing before administration.
Amneal is also pushing into more complex delivery categories. In April 2026, it launched two respiratory metered-dose inhalation products, marking its entry into complex inhalation. The company also launched bimatoprost ophthalmic solution 0.01%, a generic version of AbbVie’s (ABBV - Free Report) Lumigan, which it expects to be an important growth driver for Affordable Medicines.
Specialty delivered strong first-quarter performance, with revenue of $133 million up 23% year over year. Growth was driven by robust uptake of Crexont and steady Rytary and Unithroid growth, and the quarter included initial sales from Brekiya following its recent launch.
The near-term profile differs from the longer-term setup because 2026 includes an expected headwind. Management expects Specialty revenue growth to be roughly flat in 2026 due to anticipated generic erosion of Rytary, even as Crexont growth helps offset pressure. From 2027, management expects the segment to resume growth as Crexont and additional brands scale.
AMRX Risks Investors Should Track in 2026
The biggest segment-specific offset is Rytary’s loss of exclusivity. An authorized generic has already launched and additional generic entrants are expected, which can weigh on Specialty in 2026. That dynamic is important because Specialty products can be a key profit contributor even when they are a smaller portion of revenue.
Pricing pressure in the U.S. generics market remains another risk. Intense competition and buyer negotiating leverage can compress margins, making it harder to translate volume gains into consistent profit growth.
Finally, execution and regulatory timing matter more as the portfolio tilts toward complex injectables, biosimilars, and niche specialty products. These programs involve stricter manufacturing requirements and more rigorous FDA scrutiny, and delays or slower-than-expected uptake could derail growth expectations.
View the Zacks #1 Rank List
Image: Bigstock
What's Driving Amneal's 2026 Growth Outlook?
Key Takeaways
Amneal Pharmaceuticals (AMRX - Free Report) opened 2026 with results that reinforced its steady execution story. The company is leaning on a diversified model that blends retail generics, higher-margin specialty brands, and a government-focused distribution business. That mix helps smooth out volatility that often hits single-product drug makers.
The setup for the rest of 2026 now hinges on two factors: whether profitability continues to climb on mix and discipline, and whether the company can keep its complex product cadence on track despite a tougher pricing backdrop in generics.
AMRX’s Q1 Beat Sets the Tone for 2026
In the first quarter of 2026, adjusted earnings were 27 cents per share, up 29% year over year. Results topped the Zacks Consensus Estimate of 17 cents. Total revenue was $723 million, up 4% year over year, and also came in ahead of the $713 million consensus mark.
The beat matters because it reflects momentum across multiple parts of the business, not a one-off benefit. Affordable Medicines grew modestly, Specialty posted a sharp increase, and AvKARE stayed sizeable even with a year-over-year decline. Together, that combination supports the view that operating progress is carrying into the full year.
Amneal’s Three-Segment Model Spreads Risk
Amneal runs three reportable segments: Affordable Medicines, Specialty, and AvKARE. Affordable Medicines develops, manufactures, and sells retail generics, injectables, and biosimilars across multiple dosage forms. Specialty markets branded therapies focused primarily on neurology and endocrine disorders. AvKARE distributes pharmaceuticals and other products to the U.S. federal government, retail, and institutional markets.
The diversification is visible in the revenue mix. In fiscal 2025, total net revenue was $3.0 billion, with Affordable Medicines at $1.7 billion, Specialty at $528.5 million, and AvKARE at $744.7 million. That balance reduces reliance on any single product line and supports steadier revenue and profit progress when one segment faces temporary headwinds.
AMRX Guidance Highlights Profitability Progress
For 2026, management expects net revenue of $3.05 billion to $3.15 billion. The updated outlook kept the revenue range unchanged, but raised profitability expectations. Adjusted EBITDA is now projected at $740 million to $770 million, up from $720 million to $760 million.
Adjusted earnings per share are now expected to be 95 cents to $1.05, up from 93 cents to $1.03. The higher EBITDA and earnings ranges point to improving mix and execution rather than simply counting on faster top-line growth. In practical terms, the company is signaling that higher-value products and operating discipline can carry more of the performance load in 2026.
Amneal’s Generics Pipeline Can Reaccelerate Growth
Affordable Medicines is expected to accelerate in 2026 and 2027 versus 2025 levels. Management expects the segment’s net revenue to grow 7% to 8% in 2026. A key driver is cadence: Amneal expects to launch 20 to 30 new products in Affordable Medicines each year, with an emphasis on complex products.
The pipeline also includes biosimilars. A notable 2026 opportunity is a biosimilar version of Novartis’ (NVS - Free Report) Xolair, which is under review. If approved, Amneal would have six biosimilars in the United States. That matters for investors because biosimilars and complex generics can offer a different growth and margin profile than “plain vanilla” launches, while still serving the broader demand for affordable medicines.
AMRX Injectables Expansion Adds Differentiation
Recent product actions highlight how dosage-form differentiation can set Amneal apart. On June 4, 2026, the FDA approved romidepsin injection solution supplied in single-dose, ready-to-use vials. The product is eligible for Competitive Generic Therapy designation, which provides 180 days of market exclusivity.
Management emphasized convenience benefits versus an existing powder form that requires mixing before administration.
Amneal is also pushing into more complex delivery categories. In April 2026, it launched two respiratory metered-dose inhalation products, marking its entry into complex inhalation. The company also launched bimatoprost ophthalmic solution 0.01%, a generic version of AbbVie’s (ABBV - Free Report) Lumigan, which it expects to be an important growth driver for Affordable Medicines.
AMNEAL PHARMACEUTICALS, INC. Price and Consensus
AMNEAL PHARMACEUTICALS, INC. price-consensus-chart | AMNEAL PHARMACEUTICALS, INC. Quote
Amneal’s Specialty Brands Provide Margin Support
Specialty delivered strong first-quarter performance, with revenue of $133 million up 23% year over year. Growth was driven by robust uptake of Crexont and steady Rytary and Unithroid growth, and the quarter included initial sales from Brekiya following its recent launch.
The near-term profile differs from the longer-term setup because 2026 includes an expected headwind. Management expects Specialty revenue growth to be roughly flat in 2026 due to anticipated generic erosion of Rytary, even as Crexont growth helps offset pressure. From 2027, management expects the segment to resume growth as Crexont and additional brands scale.
AMRX Risks Investors Should Track in 2026
The biggest segment-specific offset is Rytary’s loss of exclusivity. An authorized generic has already launched and additional generic entrants are expected, which can weigh on Specialty in 2026. That dynamic is important because Specialty products can be a key profit contributor even when they are a smaller portion of revenue.
Pricing pressure in the U.S. generics market remains another risk. Intense competition and buyer negotiating leverage can compress margins, making it harder to translate volume gains into consistent profit growth.
Finally, execution and regulatory timing matter more as the portfolio tilts toward complex injectables, biosimilars, and niche specialty products. These programs involve stricter manufacturing requirements and more rigorous FDA scrutiny, and delays or slower-than-expected uptake could derail growth expectations.
AMRX’s Zacks Rank
Amneal currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.